CA9 and nonpapillary renal cell carcinoma: Two foundational clinical trials targeting CAIX with CAR T-cell therapy in metastatic clear cell RCC (ccRCC) were conducted using G250/CAIX-specific single-chain variable fragment (scFv) fused to CD3ζ (first generation).